KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Raw Materials: 2009-2025

Historic Raw Materials for Halozyme Therapeutics (HALO) over the last 13 years, with Sep 2025 value amounting to $19.0 million.

  • Halozyme Therapeutics' Raw Materials fell 37.99% to $19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.0 million, marking a year-over-year decrease of 37.99%. This contributed to the annual value of $24.0 million for FY2024, which is 1.56% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Raw Materials stood at $19.0 million for Q3 2025, which was up 6.61% from $17.8 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Raw Materials ranged from a high of $30.6 million in Q3 2024 and a low of $6.0 million during Q1 2021.
  • Over the past 3 years, Halozyme Therapeutics' median Raw Materials value was $24.0 million (recorded in 2024), while the average stood at $23.9 million.
  • In the last 5 years, Halozyme Therapeutics' Raw Materials skyrocketed by 137.50% in 2023 and then crashed by 37.99% in 2025.
  • Halozyme Therapeutics' Raw Materials (Quarterly) stood at $10.7 million in 2021, then grew by 29.24% to $13.8 million in 2022, then soared by 71.45% to $23.6 million in 2023, then grew by 1.56% to $24.0 million in 2024, then plummeted by 37.99% to $19.0 million in 2025.
  • Its Raw Materials stands at $19.0 million for Q3 2025, versus $17.8 million for Q2 2025 and $18.4 million for Q1 2025.